Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis · 2019
Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marco-Benedí Victoria, Jarauta Estíbaliz, Pérez-Calahorra Sofía, Bea Ana M, Civeira Fernando
Аннотация
A 60-year-old male with familial combined hyperlipidemia, ischemic heart disease and type 2 diabetes. Since childhood, intolerance to intense exercise. The patient was diagnosed of McArdle's disease after an episode of rhabdomyolysis associated with statins as treatment after a myocardial infarction. Since then, he had been treated with diet, fibrates and ezetimibe with good tolerance, despite this, LDL cholesterol (cLDL) remained >180mg/dl. He started to be treated with alirocumab 150mg/sc every 14 days, with excellent clinical response and a decrease in cLDL to 15mg/dl. Our case shows that PCSK9 inhibitors are effective and safe in patients with muscle diseases who have statin contraindication, and they are a good therapeutic tool for these patients.
Предметные рубрики MeSH
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLGlycogen Storage Disease Type VHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemia, Familial CombinedMaleMiddle AgedMyocardial InfarctionPCSK9 InhibitorsRhabdomyolysisRisk FactorsTreatment OutcomeProprotein Convertase 9